7 active warrant series covering 69,932,625 shares (~22.8% potential dilution); nearest expiry 2026-12-27.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| warrant | $0.10 | Dec 27, 2026 88d | 18.0M | ITM | 5.9% | C$1.8M | Auto |
| warrant | $0.06 | Dec 27, 2026 88d | 1.4M | ITM | 0.5% | C$85K | Auto |
| warrant | $0.10 | Jun 19, 2027 262d | 13.8M | ITM | 4.5% | C$1.4M | Auto |
| finder | $0.10 | Aug 30, 2027 334d | 655K | ITM | 0.2% | C$66K | Auto |
| warrant | $0.10 | Aug 30, 2027 334d | 22.1M | ITM | 7.2% | C$2.2M | Auto |
| finder | $0.15 | Sep 17, 2027 352d | 750K | ITM | 0.2% | C$113K | Auto |
| warrant | $0.15 | Sep 17, 2027 352d | 13.3M | ITM | 4.3% | C$2.0M | Auto |
Basis: Current shares & price vs as-filed warrant terms.
7 option grants covering 23,550,000 shares (~7.7% potential dilution). Counted apart from the warrants above.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| option | $0.10 | Nov 9, 2026 40d | 300K | ITM | 0.1% | C$30K | Auto |
| option | $0.05 | Apr 23, 2027 205d | 2.3M | ITM | 0.7% | C$115K | Auto |
| option | $0.10 | Jun 16, 2027 259d | 2.7M | ITM | 0.9% | C$270K | Auto |
| option | $0.15 | Oct 1, 2027 366d | 10.2M | ITM | 3.3% | C$1.5M | Auto |
| option | $0.05 | Nov 7, 2027 403d | 250K | ITM | 0.1% | C$13K | Auto |
| option | $0.15 | Nov 12, 2027 408d | 1.0M | ITM | 0.3% | C$150K | Auto |
| option | $0.05 | Aug 9, 2029 1044d | 6.8M | ITM | 2.2% | C$343K | Auto |
306,757,960 shares outstanding, plus 69,932,625 from warrants and 23,550,000 from options — a fully diluted 400,240,585 shares, or ~30.5% above today's count if every one of them is exercised.
Price history with the company's supply walls overlaid — warrants (amber), employee and consultant options (pink), and free-trading unlock dates (violet). Each wall sits at the price the paper is struck at today, restated through any consolidation, and is measured in the SHARES it can issue rather than the number of certificates. Levels and dates are Pacific Time.
7 active warrant series covering 69,932,625 shares (~22.8% potential dilution); nearest expiry 2026-12-27.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| warrant | $0.10 | Dec 27, 2026 88d | 18.0M | ITM | 5.9% | C$1.8M | Auto |
| warrant | $0.06 | Dec 27, 2026 88d | 1.4M | ITM | 0.5% | C$85K | Auto |
| warrant | $0.10 | Jun 19, 2027 262d | 13.8M | ITM | 4.5% | C$1.4M | Auto |
| finder | $0.10 | Aug 30, 2027 334d | 655K | ITM | 0.2% | C$66K | Auto |
| warrant | $0.10 | Aug 30, 2027 334d | 22.1M | ITM | 7.2% | C$2.2M | Auto |
| finder | $0.15 | Sep 17, 2027 352d | 750K | ITM | 0.2% | C$113K | Auto |
| warrant | $0.15 | Sep 17, 2027 352d | 13.3M | ITM | 4.3% | C$2.0M | Auto |
Basis: Current shares & price vs as-filed warrant terms.
7 option grants covering 23,550,000 shares (~7.7% potential dilution). Counted apart from the warrants above.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| option | $0.10 | Nov 9, 2026 40d | 300K | ITM | 0.1% | C$30K | Auto |
| option | $0.05 | Apr 23, 2027 205d | 2.3M | ITM | 0.7% | C$115K | Auto |
| option | $0.10 | Jun 16, 2027 259d | 2.7M | ITM | 0.9% | C$270K | Auto |
| option | $0.15 | Oct 1, 2027 366d | 10.2M | ITM | 3.3% | C$1.5M | Auto |
| option | $0.05 | Nov 7, 2027 403d | 250K | ITM | 0.1% | C$13K | Auto |
| option | $0.15 | Nov 12, 2027 408d | 1.0M | ITM | 0.3% | C$150K | Auto |
| option | $0.05 | Aug 9, 2029 1044d | 6.8M | ITM | 2.2% | C$343K | Auto |
306,757,960 shares outstanding, plus 69,932,625 from warrants and 23,550,000 from options — a fully diluted 400,240,585 shares, or ~30.5% above today's count if every one of them is exercised.
Price history with the company's supply walls overlaid — warrants (amber), employee and consultant options (pink), and free-trading unlock dates (violet). Each wall sits at the price the paper is struck at today, restated through any consolidation, and is measured in the SHARES it can issue rather than the number of certificates. Levels and dates are Pacific Time.
An issuer that discloses only a plan total appears as one line at its weighted-average exercise price and weighted-average remaining life — the filing's own summary, not a per-grant schedule.
An issuer that discloses only a plan total appears as one line at its weighted-average exercise price and weighted-average remaining life — the filing's own summary, not a per-grant schedule.
